RankAlpha logo
Back to Rankings

GLUE

Monte Rosa TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Bull case: Monte Rosa has a strong balance sheet, runway into 2029, and a dense 2026 catalyst calendar across NEK7, MRT-2359, and the Novartis partnership. If MRT-8102 and MRT-2359 continue to show differentiated biology, the stock can re-rate toward the low-30s, broadly consistent with the packet’s $33.8 median target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -13.7.
What can break
Clinical readout risk is the main issue: MRT-8102 GFORCE-1 could fail to show enough differentiation in H2 2026.
Momentum
75
Value
60
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $34.00 · Bear $11.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $33.80
Why
Momentum75 · Δ7d -4.2
Value60 · Δ7d +0.2
Sentiment81 · Δ7d -13.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
75
34% active weight
Current posture
7d trendFlat
Δ7d
-4.2
Δ21d
-7.5
Value
60
32% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.4
Sentiment
81
33% active weight
Current posture
7d trendSoftening
Δ7d
-13.7
Δ21d
+20.9
Why this grade

Composite grade A. Momentum 75.1 / Value 60.0 / Sentiment 81.1

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.66B
Beta
1.61
Shares Out
65.12M
P/E (TTM)
57.5
P/S (TTM)
5.17
P/FCF (TTM)
6.47
Rev YoY
+38.5%
EPS YoY
-13.0%
Gross Margin
-
Op Margin
+4.7%
Net Debt
-$372.15M
Current Ratio
6.54
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology